Antisense Pharma revises development path for trabedersen
German biopharmaceutical company Antisense Pharma has announced its revised corporate and development strategy, which include revision of its development program for its cancer drug candidate trabedersen, receiving full support from its main investors.
The updated corporate strategy focuses on streamlining the organization to meet its current business objectives and strengthen key senior management positions in light of the new direction for trabedersen’s clinical development program and the advancement of Antisense Pharma’s “Next Generation” TGF-beta inhibitor oligonucleotide program.
The data analysis of SAPPHIRE (G005), trabedersen’s early terminated Phase III study in glioma, is in progress. Due to a need for additional outcome data collection, final results are now expected within the third quarter of 2013, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze